0000899243-20-003714.txt : 20200207
0000899243-20-003714.hdr.sgml : 20200207
20200207183156
ACCESSION NUMBER: 0000899243-20-003714
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200205
FILED AS OF DATE: 20200207
DATE AS OF CHANGE: 20200207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: El-Hibri Fuad
CENTRAL INDEX KEY: 0001380185
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 20588800
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-05
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380185
El-Hibri Fuad
400 PROFESSIONAL DRIVE, SUITE 400
GAITHERSBURG
MD
20879
1
1
1
0
Executive Chairman
Common Stock
2020-02-05
4
S
0
48316
60.66
D
1430702
D
Common Stock
2020-02-06
4
S
0
11684
61.90
D
1419018
D
Common Stock
4344250
I
By Intervac, L.L.C.
Common Stock
1524155
I
By Biovac, L.L.C.
All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act").
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.90 to $61.90.
Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
/s/ Carl A. Valenstein, attorney-in-fact
2020-02-07